Cargando…

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer

PURPOSE: We compared the efficacy, survival rate, and adverse events between bicalutamide 150-mg monotherapy and combined androgen blockade (CAB) in men with locally advanced prostate cancer. MATERIALS AND METHODS: From March 2003 to July 2012, we retrospectively included 74 patients who were treate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Yu Jin, Kim, Ki Ho, Lee, Kyung Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026657/ https://www.ncbi.nlm.nih.gov/pubmed/24868335 http://dx.doi.org/10.4111/kju.2014.55.5.315

Ejemplares similares

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
por: Dijkstra, Siebren, et al.
Publicado: (2016)

Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only
por: Latz, Stefan, et al.
Publicado: (2015)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
por: Culig, Z, et al.
Publicado: (1999)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure
por: Muramatsu, Tomoaki, et al.
Publicado: (2019)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

Charge density view on bicalutamide molecular interactions in the monoclinic polymorph and androgen receptor binding pocket
por: Korlyukov, Alexander A., et al.
Publicado: (2020)

Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
por: Fujimura, Tetsuya, et al.
Publicado: (2018)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy
por: Giorgetti, Elisa, et al.
Publicado: (2015)

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer
por: Johnson, Tamara Jane, et al.
Publicado: (2013)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
por: Li, Yuezheng, et al.
Publicado: (2023)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer
por: Miyazaki, Toshiaki, et al.
Publicado: (2015)

Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients
por: Liu, Jinan, et al.
Publicado: (2013)

Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report
por: Sheth, Hardik, et al.
Publicado: (2021)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
por: Tian, Lei, et al.
Publicado: (2022)

Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K–PKB activity
por: Zhang, Yu, et al.
Publicado: (2022)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
por: Iwamoto, Hiroaki, et al.
Publicado: (2022)

Bicalutamide-induced hepatotoxicity: A rare adverse effect
por: Hussain, Salwa, et al.
Publicado: (2014)

Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia
por: Gomez-Zubiaur, Alba, et al.
Publicado: (2023)

Efficacy of 0.4 mg tamsulosin monotherapy in patients with moderate-to-severe lower urinary tract symptoms
por: Kang, Tae Wook, et al.
Publicado: (2021)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?
por: Lewis, R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fcro06lur95jmmtg8l91tg8itf